key: cord-0871594-wtfa1kbw authors: Ramachandran, Anu; Noble, Jeanne; Deucher, Anne; Miller, Steve; Tang, Patrick Wai; Wang, Ralph C title: Performance of Abbott ID‐Now rapid nucleic amplification test for laboratory identification of COVID‐19 in asymptomatic emergency department patients date: 2021-12-29 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12592 sha: 3fb7fb9940f954e48c880f620e56f51e0066a425 doc_id: 871594 cord_uid: wtfa1kbw OBJECTIVE: We sought to evaluate the test characteristics of Abbott ID‐Now as a screening tool compared to polymerase chain reaction (PCR) testing for identification of COVID in an asymptomatic emergency department population. METHODS: We performed a prospective study enrolling a convenience sample of asymptomatic patients presenting to a single academic emergency department (ED) who received simultaneous testing with ID‐Now and PCR per standardized ED protocols. Sensitivity, specificity, and positive and negative predictive value (PPV, NPV) of ID‐Now were calculated compared to PCR. Stratified analysis by cycle threshold (Ct) values was also performed, defined as high viral load (Ct < 33) and low viral load (Ct ≥ 33). RESULTS: A total of 3121 patients were enrolled, of whom 2895 had valid results for ID‐Now and PCR. COVID prevalence was 2.6%. ID‐Now had a sensitivity of 85.1% (95% CI 75.9% to 92.7%) and a specificity of 99.7% (99.5% to 99.9%). PPV and NPV were high at 87.5% (83.1% to 96.1%) and 99.6% (99.3% to 99.8%). Stratified analysis by low and high Ct values demonstrated reduction in sensitivity in patients with low viral loads: 91.7% (81.6% to 97.2%) in low Ct value patients versus 58.3% (27.7% to 84.8%) in high Ct value patients. CONCLUSIONS: ID‐Now had excellent performance in asymptomatic ED patients with a low rate of false positives. Cycle threshold analysis suggests a relationship between viral load and ID‐Now sensitivity. Given its speed and performance in this population, ID‐Now should be considered an excellent tool to support clinical decision‐making in ED populations. The Use of the ID-Now offers an important opportunity for timely diagnosis, with the potential to mitigate infectious risk to others by identifying and isolating asymptomatic patients from shared waiting and treatment areas. A few studies have examined the performance of ID-Now compared to standard-of-care testing modalities and reported sensitivities from 75% to 93%. [1] [2] [3] [4] However, existing literature focuses on symptomatic patients with clinical concern for COVID infection and uses swabs in viral transport media, whereas the currently approved protocol for the ID-Now is a dry nasal swab. A recent study also raised concerns about the sensitivity of the ID-Now for patients with low viral loads; 33%-45% of patients with low viral loads were considered falsely negative. 5 Thus, reevaluation of the ID-Now in an asymptomatic patient population, using the manufacturer-indicated dry nasal swab, was performed to improve our understanding of this assay and justify its use in clinical settings, particularly in the ED. The objective of this study was to determine the diagnostic performance of the ID-Now COVID-19 assay for the evaluation of asymptomatic ED patients compared to the current gold standard RT-PCR testing. Specifically, we determined the sensitivity, specificity, likelihood ratios (LR), and positive and negative predictive values (PPV, NPV) of the ID-Now. We also determined these metrics in those with low and high viral loads as defined by cycle threshold (Ct) values above and below 33. With We conducted a retrospective study of the ID-Now in patients presenting to a single ED at a large, tertiary care hospital. We collected data from our electronic medical record via convenience sampling during a 5-month period from July 23, 2020 to December 14, 2020. During this time period, citywide mask mandates and closure of non-essential businesses were in place, and the overall prevalence of COVID infection in the city was low. Our study was approved by institutional review board and we adhered to Standards for Reporting Diagnostic accuracy studies (STARD) reporting guidelines. The study took place at University of California at San Francisco (UCSF) Medical Center, an urban academic ED caring for approximately 45,000 patients annually. Adult participants (over age 18 years) were all patients presenting to the ED during the specified dates who were tested with both ID-Now and RT-PCR as part of standard ED protocol. According to this protocol, the triage nurse or physician screened all patients for COVID symptoms (defined as fever, respiratory symptoms, diarrhea, or myalgias) or for a known COVID-positive contact. Those without COVID symptoms or a known COVID-positive contact were determined to be low risk. Patients with low concern for COVID infection and those meeting the following criteria received both ID-Now and RT-PCR testing, with swabbing performed simultaneously: patients triaged to shared rooms (including the observation unit or hallway beds), patients unable to self-isolate (congregate living, experiencing homelessness, dialysis) and patients whose estimated waiting room time exceeded 1 hour. We excluded patients who did not obtain both tests. ID-Now (Index test) was performed by ED nurses or patient care technicians (PCTs) who had completed standardized training in accordance with manufacturer recommendations. Samples were collected via mid-turbinate dry nasal swab and tested immediately using the ID-Now instrument, located in the ED. Diagnostic accuracy of the ID-Now index text was determined by calculating sensitivity, specificity, PPV, NPV, and LRs, along with 95% con- Over Test characteristics of ID-Now are summarized in Table 2A . Figure 2 shows the Ct values of all RT-PCR positive patients, demonstrating the relationship between falsenegative ID-Now testing and higher Ct values. Our study has a few important limitations. It is a single-center study using a convenience sample, which limits its generalizability. The evolving nature of the pandemic meant that ED protocols were not consistent throughout the study period. less likely to display symptoms), and a reduction in sensitivity was seen in this population as well. Patients shedding low amounts of virus appear to be less infectious, and the benefit of a rapid result with high sensitivity to identify infectious patients is of considerable use in the initial patient management decisions in the ED. 8 Our results suggest that ID-Now is a reliable tool for COVID screening for asymptomatic patients in the ED setting. Although our Ct analysis suggests a relationship between viral load and sensitivity of ID-Now, the overall sensitivity of ID-Now remained high. The poor sensitivity of ID-Now in the small number of patients with high Ct values suggests more research is needed to evaluate the performance of ID-Now in patients with low viral loads. The fact that ID-Now can be performed with a rapid turnaround time using machines within the ED offers several benefits, most important, cohorting of patients by COVID status. Rapid testing allows more precise risk assessment before aerosolizing procedures in the ED or the operating room. Discharging patients experiencing homelessness or to congregate living situations can also be expedited. Rapid testing within the ED setting has also been associated with less time in isolation and reduced use of personal protective equipment. 8 In summary, rapid and reliable COVID testing allows for safer and more effective care of ED patients. Our study demonstrates that ID-Now demonstrates excellent sensitivity and specificity in a cohort of ED patients. Given the numerous benefits of rapid turnaround time and strong performance in this population, ID-Now should be considered an excellent screening tool to support clinical decision-making in ED populations. The authors have no conflicts of interest to disclose. Anu Ramachandran, Jeanne Noble, and Ralph Wang conceived and designed the study. Jeanne Noble, Anu Ramachandran, Ralph C Wang, and AD oversaw clinical data collection-Anne Deucher, Steve Miller and Patrick Wai Tang procured microbiological data. Anu Ramachandran performed the statistical analysis with oversight by Jeanne Noble and Ralph C Wang. Anu Ramachandran drafted the manuscript, and all authors contributed substantially to its revision. Anu Ramachandran MD https://orcid.org/0000-0002-9038-1825 Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2 Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic Comparison of Abbott ID Now and abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral media and dry nasal swabs in a New York City academic institution Comparison of abbott ID now, diaSorin simplexa, and cdc fda emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19 Targeted rapid testing for SARS-CoV-2 in the emergency department is associated with large reductions in uninfected patient exposure time